Are you Dr. Huang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
Thoracic Oncology Cancer Center
Palo Alto, CA 94304Phone+1 650-498-6000
Summary
- Dr. Jane Huang, MD is a hematologist in Palo Alto, California.
Publications & Presentations
PubMed
- 25 citationsZanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien
Journal of Clinical Oncology. 2023-02-10 - 7 citationsUse of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.Michael F Gensheimer, Divya Gupta, Manali I Patel, Touran Fardeen, Rachel Hildebrand
JCO Oncology Practice. 2023-02-01 - 41 citationsZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01
Press Mentions
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (Zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-cell MalignanciesDecember 11th, 2021- ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa Fleshes Out Competitive Leukemia Data AgainNovember 4th, 2021
- BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual MeetingNovember 4th, 2021
- Join now to see all
